The downgrade by a reputable analyst like Michael Petusky from Barrington Research can influence investor sentiment and potentially lead to a neutral or slightly negative short-term impact on ModivCare's stock price. However, the change to 'Market Perform' suggests a lack of strong negative catalysts, hence the neutral score.